Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHSCT for Early Onset Type 1 Diabetes
NCT00807651Phase 2Completed
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Feb 2008
- Primary completion
- Jun 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous hematopoietic stem cells in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Exogenous insulin dose at 36 months. Started Feb 2008; status: completed.
02
Drugs
autologous hematopoietic stem cells
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00807651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00807651.